Company news

Share this article:
Johnson & Johnson has announced plans to acquire Omrix Biorpharmaceuticals for $438 million. Omrix is expected to operate as a stand-alone entity reporting through J&J-subsidiary Ethicon. Ethicon currently holds exclusive distribution rights for Omrix's Evithrom and Evicel, two biologic-based hemostats.
 
Roche boosted its presence in the Alzheimer's sector with a merger agreement with Memory Pharmaceuticals. Under terms of the agreement, Roche will acquire Memory in a deal worth $50 million. Montvale, NJ-based Memory develops drugs for the treatment of central nervous system disorders such as Alzheimer's disease and schizophrenia. Memory and Roche already have an R&D partnership including a Phase II trial for Alzheimer's and schizophrenia and a Phase I trial for Alzheimer's. Basel, Switzerland-based Roche, which already has a major stake in the Alzheimer's pipeline, expects Memory's work to be fully integrated into Roche's R&D portfolio including the future development of its promising nicotinic alpha-7 agonists. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.